IRIS
ESPOSITO, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.025
AS - Asia 2.532
EU - Europa 2.356
SA - Sud America 329
AF - Africa 42
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.290
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.941
SG - Singapore 1.268
RU - Federazione Russa 780
IE - Irlanda 698
CN - Cina 500
HK - Hong Kong 312
BR - Brasile 275
VN - Vietnam 257
DE - Germania 167
UA - Ucraina 157
FR - Francia 118
IT - Italia 110
FI - Finlandia 97
GB - Regno Unito 67
SE - Svezia 58
IN - India 42
CA - Canada 38
TR - Turchia 31
MX - Messico 30
JP - Giappone 23
AR - Argentina 18
BD - Bangladesh 17
NL - Olanda 17
BE - Belgio 16
IQ - Iraq 14
PL - Polonia 14
ES - Italia 12
ID - Indonesia 12
LT - Lituania 12
ZA - Sudafrica 12
CO - Colombia 11
AT - Austria 9
CZ - Repubblica Ceca 8
VE - Venezuela 7
PH - Filippine 6
PK - Pakistan 6
SA - Arabia Saudita 6
MA - Marocco 5
NP - Nepal 5
PE - Perù 5
TN - Tunisia 5
DZ - Algeria 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
CR - Costa Rica 3
EC - Ecuador 3
HN - Honduras 3
HU - Ungheria 3
KR - Corea 3
MY - Malesia 3
TH - Thailandia 3
TW - Taiwan 3
AO - Angola 2
AU - Australia 2
AZ - Azerbaigian 2
BO - Bolivia 2
EG - Egitto 2
GA - Gabon 2
GT - Guatemala 2
IL - Israele 2
JM - Giamaica 2
JO - Giordania 2
KE - Kenya 2
OM - Oman 2
PT - Portogallo 2
PY - Paraguay 2
RS - Serbia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CD - Congo 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GM - Gambi 1
GN - Guinea 1
GR - Grecia 1
HT - Haiti 1
KG - Kirghizistan 1
LB - Libano 1
LU - Lussemburgo 1
MK - Macedonia 1
MZ - Mozambico 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
RO - Romania 1
SI - Slovenia 1
SR - Suriname 1
TO - Tonga 1
Totale 10.290
Salva come PNG Salva come JPEG
Città #
Singapore 710
Dallas 708
Dublin 696
Jacksonville 613
San Jose 597
Chandler 469
Ashburn 345
Hong Kong 306
Santa Clara 283
The Dalles 202
Boardman 156
Moscow 154
New York 116
Beijing 111
Council Bluffs 106
Lawrence 102
Princeton 102
Ho Chi Minh City 75
Nanjing 75
Ann Arbor 71
Wilmington 66
Hanoi 64
Los Angeles 62
Lappeenranta 56
Dearborn 55
Lauterbourg 47
Munich 39
São Paulo 31
Orem 29
Columbus 28
Shenyang 24
Helsinki 22
Nanchang 22
Tokyo 21
Rome 19
Jinan 18
Hebei 17
London 17
Frankfurt am Main 16
Jiaxing 16
Brooklyn 15
Brussels 15
Denver 15
Hefei 15
Chennai 14
Montreal 14
Turku 14
Chicago 13
Des Moines 13
Houston 13
Manchester 13
Warsaw 13
Da Nang 12
Haiphong 12
Izmir 12
San Mateo 12
Amsterdam 11
San Francisco 11
Atlanta 10
Boston 10
Changsha 10
Mexico City 10
Stockholm 10
Nuremberg 9
Assago 8
Brno 8
Curitiba 8
Mumbai 8
Norwalk 8
Seattle 8
Woodbridge 8
Falkenstein 7
Jakarta 7
Johannesburg 7
Kunming 7
Milan 7
Ningbo 7
Paris 7
Tianjin 7
Baghdad 6
Biên Hòa 6
Mountain View 6
Bogotá 5
Brasília 5
Dhaka 5
Dong Ket 5
Guangzhou 5
New Delhi 5
Phoenix 5
Pune 5
Toronto 5
Zhengzhou 5
Ankara 4
Bắc Ninh 4
Campinas 4
Can Tho 4
Cebu City 4
Charlotte 4
Florence 4
Fremont 4
Totale 7.174
Salva come PNG Salva come JPEG
Nome #
The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients 132
Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort 131
Exploring the interplay of atopic dermatitis severity with sleep and mental health: a case-control study in adult patients 129
Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. 126
Frequency of melanocytic nevi in psoriatic patients is related to treatment and not to disease severity 115
CONTINUOUS TREATMENT OF PLAQUE-TYPE PSORIASIS WITH ETANERCEPT: AN OBSERVATIONAL LONG-TERM EXPERIENCE 113
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis 111
Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis 110
A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy 108
Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study 107
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 106
AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History 103
Management of Cutaneous Squamous Cell Carcinoma of the Scalp in Kidney Transplant Recipients 102
Impact of COVID-19 Pandemic on Delay of Melanoma Diagnosis: A Systematic Review and Meta-Analysis 102
Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24-week real-life experience 100
Potential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress 98
Muir-Torre syndrome with fatal outcome 96
Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience 96
Cytokine profile characterization of naïve patients with psoriasis and psoriatic arthritis: implications for a pathogenic disease continuum 93
Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study 92
Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study 90
Interobserver agreement on dermoscopic features of pigmented basal cell carcinoma 89
Systemic treatment: Ciclosporin 88
Histopathology of the skin in rheumatic diseases 88
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic 88
Cutaneous body image in psoriasis: The role of attachment style and alexithymia 88
Dermatiti da Piogeni o Piodermiti 87
Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasis 87
Influence and variation of the body mass index (BMI) in patients treated with etanercept for plaque-type psoriasis 86
Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study 86
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis 85
Treatment of erytrodermic psoriasis with etanercept 84
Interobserver agreement on dermoscopic features of pigmented basal cell carcinoma 83
Treatment of erythrodermic psoriasis with etanercept 83
Treatment of early stage mycosis fungoides with topical bexarotene 81
A case of generalized pustular psoriasis and arthritis treated with ixekizumab 81
Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study 81
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 80
Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study 79
Quality of life 79
An Italian study on psoriasis and depression 79
Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice 78
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study 78
Brodalumab for severe hidradenitis suppurativa: a case of clinico-radiologic improvement and literature review 77
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. 77
Clinical applications of PPI-TT guidelines on transitioning therapies in the treatment of moderate to severe psoriasis: an expert opinion of central Italy dermatologists 77
Involvement of Ig heavy chain HS1,2-A enhancer*2 allele in dermatitis herpetiformis, plaque psoriasis and psoriatic arthritis 77
INFLUENCE AND VARIATION OF THE BODY MASS INDEX IN PATIENTS TREATED WITH ETANERCEPT FOR PLAQUE-TYPE PSORIASIS 77
Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis 77
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis 77
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis 77
Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care 77
A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years 76
Haplotypes associated with alleles of the immunoglobulin heavy chain enhancer HS1,2 of the 3¢ regulatory region in patients with psor- iatic arthritis 76
Association between psoriasis and periodontitis, and efficacy of anti-TNF-α therapy: a case series 76
Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients 76
Dimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic 76
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic 76
Psoriasis target therapy: ustekinumab 75
PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study 75
Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations 74
Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis 74
UVA1 Laser in the Treatment of Vitiligo 74
Morbid obesity and psoriasis: Disease remission after laparoscopic sleeve gastrectomy 74
Depressive symptoms and insecure attachment predict disability and quality of life in psoriasis independently from disease severity 74
Unresponsiveness to etanercept: is there a common phenotipical profile of patients? 73
Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. 73
Efficacy and safety of infliximab in teh treatment of severe or arthropathic psoriasis: preliminary results 73
High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: Efficacy, safety and impact on patients' quality of life 73
PsoBioVax: A multicentric Italian case–control study of the immunological response to anti-SARS-CoV-2 vaccine among psoriatic patients under biological therapy 72
Clinical Variants 72
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. 72
Psoriasis and its management in women of childbearing age: Tools to increase awareness in dermatologists and patients 72
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis 72
Self-Assessment Questionnaire on Patient-Physician Concordance on Nevus Self-Count and Models Development to Predict High-Risk Phenotype >50 Nevi 71
Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis 71
Use of etanercept in patients with psoriasis and concomitant hepatitis C infection 71
Association between Psoriasis and haplotypes of the IgH 3' Regulatory Region 1 70
Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept. 70
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis 70
Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series 70
High-dose initiation of etanercept in plaque psoriasis and psoriatic arthritis: an italian experience 69
Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis 69
Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse 69
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy 69
Some considerations about the importance of alliance between patients and dermatologists in psoriasis 69
Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice 69
Survival rate of antitumour necrosis factor- treatments for psoriasis in routine dermatological practice: a multicentre observational study 68
Dermatiti da piogeni o piodermiti 68
UVB 308 nm XeCl excimer laser for mycosis fungoides 68
Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis. 68
Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience 66
Differences in percutaneous absorption in normal and atopic dermatitis skin in relation to molecular weigh. 66
Resolution of idiopathic recurrent pericarditis in a psoriatic arthritis patient treated with etanercept 66
Long-lasting remission of pemphigus vulgaris treated with rituximab 66
Long-term efficacy of etanercept in hidradenitis suppurativa. 65
Betamethasone valerate dressing is non-inferior to calcipotriol-betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial 65
Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy 65
Effect of anti tumor necrosis factor-alpha therapies on body composition in patients with psoriasis 62
Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management 62
Totale 8.181
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.565
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.565
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021113 0 0 0 0 0 0 0 0 0 6 94 13
2021/2022334 7 4 19 11 24 4 3 25 66 4 37 130
2022/20231.613 121 66 15 139 98 133 5 99 840 10 58 29
2023/2024321 59 25 35 27 25 88 4 7 0 22 6 23
2024/20252.106 52 30 171 66 308 163 329 106 520 61 133 167
2025/20264.636 213 357 512 437 367 252 1.022 354 507 615 0 0
Totale 10.496